| Patents for A61P 27 - Drugs for disorders of the senses (53,017) |
|---|
| 02/26/2009 | US20090054505 such as 5-(3-((R)-3-(4-((S)-1-hydroxyhexyl)phenyl)-4-oxooxazolidin-2-yl)propyl)thiophene-2-carboxylic acid, used for the reduction of intraocular pressure and treament of glaucoma |
| 02/26/2009 | US20090054442 Method of administering ophthalmic fluids |
| 02/26/2009 | US20090054424 Optically active pyridine derivative and a medicament containing the same |
| 02/26/2009 | US20090054406 Compositions and Methods for Modulating Endophthalmitis Using Fluoroquinolones |
| 02/26/2009 | US20090054365 RNAi-MEDIATED INHIBITION OF AQUAPORIN 1 FOR TREATMENT OF OCULAR NEOVASCULARIZATION |
| 02/26/2009 | US20090053816 Hemoglobin-based methods for prophylaxis, diagnosis and/or treatment of retinal disorders |
| 02/26/2009 | US20090053805 Post-partum mammalian placenta, its use and placental stem cells therefrom |
| 02/26/2009 | US20090053292 Moraxella catarrhalis protein, nucleic acid sequence and uses thereof |
| 02/26/2009 | US20090053283 such as vulvodynia via comprising administering polyarginine; for treatment and/or prevention of glaucoma, pulmonary hypertension, asthma, chronic obstructive pulmonary disease, erectile dysfunction, Raynaud's syndrome, heparin overdose, vulvodynia, and wound healing agents |
| 02/26/2009 | US20090053229 Methods of Treating Conditions Involving Neuronal Degeneration |
| 02/26/2009 | US20090053190 Biodrugs comprising polypeptides and carriers comprising bioadhesives such as fibrin, for treatment of vision defects; chimeric C3-like Rho antagonists and their use for promoting repair and neuron survival in injured mammalian central and peripheral nervous system and for treating cancer |
| 02/26/2009 | CA2688215A1 The use of substances for the treatment of loss of eyesight in humans with glaucoma and other degenerative eye diseases |
| 02/25/2009 | EP2027872A1 Neurotoxic component of a botulinum toxin for treating a facial disease |
| 02/25/2009 | EP2027082A1 12-aryl or heteroaryl prostaglandin analogs |
| 02/25/2009 | EP2027081A2 Therapeutic prostaglandin compounds for the treatment of glaucoma |
| 02/25/2009 | EP2026828A1 Use of at least one polyphenol for promoting eye health |
| 02/25/2009 | EP2026786A2 Use of choline-based preparations for the treatment of tinnitus |
| 02/25/2009 | EP1878732B1 HIGHLY SELECTIVE Rho-KINASE INHIBITOR |
| 02/25/2009 | EP1751612B1 Methods and compositions for the treatment of uveitis |
| 02/25/2009 | EP1247532B1 Composition promoting lacrimal secretion |
| 02/25/2009 | EP1169050B1 Ocular treatment using cyclosporin-a derivatives |
| 02/25/2009 | EP1143965B1 Carbocyclic potassium channel inhibitors |
| 02/25/2009 | EP1075277B1 Methods for detecting and inhibiting angiogenesis |
| 02/25/2009 | CN101371925A Nano silver-cell growth factor sustained-release composite body as well as preparation method and use thereof |
| 02/25/2009 | CN101371899A Medicine for treating tympanitis |
| 02/25/2009 | CN101371828A Hypocrellin liposome preparation and preparation method thereof |
| 02/25/2009 | CN100463693C Interferon oculentum |
| 02/25/2009 | CN100463685C Medicine for treating acute secretory tympanitis and its preparing method |
| 02/25/2009 | CN100463681C Artificial tears for treating xerophthalmia |
| 02/25/2009 | CN100463668C Reversibly hot gelified water soluble medicine composition |
| 02/24/2009 | US7495109 Nociceptin analogs |
| 02/24/2009 | US7494661 Methods for using tetanus toxin for beneficial purposes in animals (mammals) |
| 02/24/2009 | CA2426221C New neurokinin antagonists, processes for preparing them and pharmaceutical compositions containing these compounds |
| 02/24/2009 | CA2356912C Pharmaceutical compositions for the treatment of ocular hypertension or glaucoma |
| 02/24/2009 | CA2262582C Hcg and derivatives as matrix metalloproteases inhibitors |
| 02/20/2009 | CA2597971A1 Method and composition for repairing epithelial and other cells and tissue |
| 02/19/2009 | WO2009023877A2 Formulations for treatment of ocular diseases or conditions |
| 02/19/2009 | WO2009023411A1 Compositions and methods for treating or controlling anterior- and posterior-segment ophthalmic diseases |
| 02/19/2009 | WO2009022897A2 Synergistic pharmaceutical composition useful for inhibiting corneal and retinal neovascularization (angiogenesis), and in other organs, in a human being or animal |
| 02/19/2009 | WO2009022687A1 Phenylacetic acid compound |
| 02/19/2009 | WO2008111590A3 Ampa and nmda receptor antagonists for neurodegenerative diseases |
| 02/19/2009 | US20090048435 Oligonucleotide modulation of cell adhesion |
| 02/19/2009 | US20090048261 Pharmaceutical Composition for Treatment of Ocular Hypertension |
| 02/19/2009 | US20090048224 Compounds and methods of use |
| 02/19/2009 | US20090048219 Organic nitric oxide donor salts of nonsteroidal antiinflammatory compounds, compositions and methods of use |
| 02/19/2009 | US20090048201 Use of targeted cross-linked nanoparticles for in vivo gene delivery |
| 02/19/2009 | US20090048188 Ophthalmic medicine composition |
| 02/19/2009 | US20090048161 Cytokine receptor modulators and uses thereof |
| 02/19/2009 | US20090047258 Compositions and methods for reversing age-related changes in extracellular matrix proteins |
| 02/19/2009 | CA2736382A1 Synergistic pharmaceutical composition useful for inhibiting corneal and retinal neovascularization (angiogenesis), and in other organs, in a human being or animal |
| 02/19/2009 | CA2695757A1 Phenylacetic acid compound |
| 02/18/2009 | EP2026073A1 Diagnostics and therapeutics for macular degeneration-related disorders |
| 02/18/2009 | EP2025754A2 Moraxella (Branhamella) catarrhalis antigens |
| 02/18/2009 | EP2025676A1 Novel indazole derivative having spiro ring structure in side chain |
| 02/18/2009 | EP2025336A1 Retinyl derivatives for treating ophtalmic conditions |
| 02/18/2009 | EP2024498A2 Protection against and treatment of age related macular degeneration |
| 02/18/2009 | EP2023945A2 Composition for improving eye health |
| 02/18/2009 | EP2023918A2 Method for the treatment and prevention of ocular disorders |
| 02/18/2009 | EP1614684B1 Diamine derivative, production process, and antioxidizing drug |
| 02/18/2009 | EP1513493B1 Analgesics |
| 02/18/2009 | EP1501530B1 Prostaglandin f2 alpha analogs in combination with antimicrobial for treating glaucoma |
| 02/18/2009 | EP1463563B1 Superoxide dismutase mimics for the treatment of ocular disorders and diseases |
| 02/18/2009 | EP1028945B9 Substituted pyridine compounds as anti-inflammatory agents |
| 02/18/2009 | CN101370521A Remedy for disease associated with choroidal angiogenesis |
| 02/18/2009 | CN101370505A Treatment of ocular neovascular disorders such as macular degeneration, angiod streaks, uveitis and macular edema |
| 02/18/2009 | CN101366881A Traditional Chinese medicine for treating acute infectious conjunctivitis |
| 02/18/2009 | CN101366529A Xanthophyll nourishing beverage, xanthophyll milk |
| 02/18/2009 | CN100462359C 5-sulfanyl-4H-1,2,4-triazole derivatives and their use as a medicament |
| 02/18/2009 | CN100462352C Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents |
| 02/18/2009 | CN100462351C Amino acids with affinity for the alpha-2-delta-protein |
| 02/18/2009 | CN100462074C Chewing tablet with vision fatigue relieving function |
| 02/17/2009 | US7491733 Bicyclic guanidine derivatives and therapeutic uses thereof |
| 02/17/2009 | US7491730 Compositions useful as inhibitors of GSK-3 |
| 02/17/2009 | US7491410 Food grade transglutaminase inhibitor and uses thereof |
| 02/17/2009 | US7491392 An isolated IL-1 beta binding molecule comprising a heavy chain variable domain; treatment of an IL-1 mediated disease or disorder, e.g. osteoarthritis, osteroporosis and other inflammatory arthritis |
| 02/17/2009 | CA2445189C Carboline derivatives as pdev inhibitors |
| 02/16/2009 | CA2640986A1 Therapeutic compositions for treatment of inflammation of ocular and adnexal tissues |
| 02/12/2009 | WO2009021155A1 Histone deacetylase inhibitors for treating degenerative diseases of the eye |
| 02/12/2009 | WO2009020145A1 Two-component eye drops containing pirenoxine |
| 02/12/2009 | WO2009020119A1 Pharmaceutical containing hif-1 alpha and hif-2 alpha expression inhibitor |
| 02/12/2009 | WO2009019712A1 Novel xanthophyll composition contaning (trans, meso) - zeaxanthin, and a process for its preparation |
| 02/12/2009 | WO2009019555A2 Ophthalmic formulation containing paracetamol |
| 02/12/2009 | WO2008045663A3 Aryl-substituted heterocyclic pde4 inhibitors as antiinflammatory agents |
| 02/12/2009 | US20090042962 Therapeutic Agent for Keratoconjunctival Disorder |
| 02/12/2009 | US20090042953 IMIDAZO [2,1,-b]-1,3,4-THIADIAZOLE SULFONAMIDES |
| 02/12/2009 | US20090042933 Derivatives of 4-(2-amino -1-hydroxyethyl)phenol as agonists of the Beta2 adrenergic receptor |
| 02/12/2009 | US20090042893 Kinase inhibitors, compositions comprising them, and methods of their use |
| 02/12/2009 | US20090042885 2-(2-((2R)-2-heptylaminomethyl-5-oxopyrrolidin-1-yl)ethylthio)-1,3-thiazole-4-carboxylic acid; EP2 and/or EP4 receptor agonist; immune disease; antiallergens; alopecia; dysmenorrhea; erectile dysfuncction; antiarthritic agents; liver, respiratory, vascular, urogenital disorder |
| 02/12/2009 | US20090042866 Tetrahydrocarbazoles as Active Agents for Inhibiting VEGF Production by Translational Control |
| 02/12/2009 | US20090042834 Stabilized Glycosaminoglycan Preparations and Related Methods |
| 02/12/2009 | US20090042778 Methods for Suppressing Neovascularization Using Ephrinb2 |
| 02/12/2009 | US20090042270 Activatable recombinant neurotoxins |
| 02/12/2009 | US20090042199 Nucleotide sequences coding lymphocyte adhesion protein for use in treatment of autoimmunity, inflammation and infection |
| 02/12/2009 | US20090041855 Therapeutic agent for ophthalmic diseases |
| 02/12/2009 | US20090041828 Insert for the treatment of dry eye |
| 02/12/2009 | US20090041785 Use of anti-integrin antibodies for reducing scar tissue formation |
| 02/12/2009 | US20090041666 Ophthalmic formulations of Amyloid-beta contrast agent and methods of use thereof |
| 02/12/2009 | CA2698752A1 Oral cannabinoid liquid formulations and methods of treatment |
| 02/11/2009 | EP2021026A1 Use of il-i antibodies for treating ophthalmic disorders |
| 02/11/2009 | EP1478236B1 Targeted retrograde gene delivery to motor neurons |